InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,178.00
(
-0.45%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
-0.66%
)
Bitcoin
60,242.47
(
-2.22%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119954
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 215745

Wednesday, 12/06/2017 5:59:19 PM

Wednesday, December 06, 2017 5:59:19 PM

Post# of 252426
Dysport chronology...

Ipsen is the inventor of Dysport and owns the worldwide rights for therapeutic indications.

For cosmetic indications only, Ipsen licensed Dysport's North America rights to Medicis, who was acquired by Valeant in 2012 (#msg-79186818). In 2014 (#msg-102583917), Valeant sold its Dysport rights to Galderma, who had acquired the ex-North America Dysport rights for cosmetic indications in 2007 (#msg-136697806).

Nestlé recently bought out L'Oreal's 50% stake in Galderma, so now Nestlé (d/b/a Nestlé Skin Health) is Galderma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up